Molecure SA

As of March 31, 2025, Molecure SA carries a market capitalization of 44.25M, placing it among publicly traded companies globally. Its enterprise value stands at 36.12M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Molecure SA's next confirmed earnings release is scheduled for October 30, 2026.

As of March 31, 2025, Molecure SA has 20.20M shares outstanding.

These figures are as of March 31, 2025.

As of March 31, 2025, Molecure SA maintains a current ratio of 10.28, meaning it holds 10.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 6.81, indicating elevated leverage, while an interest coverage ratio of -448.15 demonstrates limited ability to service its debt obligations.

Over the twelve months ended March 31, 2025, Molecure SA posted a negative return on equity (ROE) of -30.82, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -27.41, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 106.50, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Molecure SA's stock has declined approximately 21.18% over the past 52 weeks. The 50-day moving average sits at 1.54, while the 200-day moving average is 1.47.

Over the twelve months ended March 31, 2025, Molecure SA generated - - in revenue and converted that into -7.09M in net income, yielding earnings per share of -0.41. EBITDA reached -6.72M, while operating income came in at -7.32M.

As of March 31, 2025, Molecure SA holds 9.72M in cash and equivalents against 1.60M in total debt, resulting in a net debt position of -9.72M. Total book value stands at 23.48M, with working capital of 8.97M providing operational flexibility.

Molecure SA produced -6.70M in operating cash flow over the twelve months ended March 31, 2025. After subtracting -100,667.76 in capital expenditures, free cash flow totaled -6.80M - equivalent to -0.37 per share.

These figures cover the twelve months ended March 31, 2025. Free cash flow yield is negative at -17.84: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -17.51, meaning Molecure SA raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of March 31, 2025, Molecure SA has an Altman Z-Score of 8.50, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.